Present inventions demonstrates that NHE-1 inhibiting carbonylguanidine derivatives inhibit a-synuclein toxicity. Such compounds can be used in the treatment or prevention of synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA).
BAEKELANDT VEERLE [BE]; BUETTNER SABRINA [AT]; GERARD MELANIE [BE]; MADEO FRANK [AT]; WINDERUCJX JORIS [BE]
Type of Offer:
« More Biotech Patents